US Bancorp DE Buys 1,327 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

US Bancorp DE boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 70.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 3,223 shares of the company’s stock after purchasing an additional 1,327 shares during the quarter. US Bancorp DE’s holdings in Apellis Pharmaceuticals were worth $103,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. State of New Jersey Common Pension Fund D increased its stake in Apellis Pharmaceuticals by 10.1% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 49,795 shares of the company’s stock valued at $1,436,000 after buying an additional 4,554 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth $824,000. KBC Group NV increased its holdings in shares of Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares during the period. Landscape Capital Management L.L.C. bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth $776,000. Finally, Charles Schwab Investment Management Inc. grew its position in Apellis Pharmaceuticals by 1.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 956,362 shares of the company’s stock worth $27,581,000 after acquiring an additional 9,328 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Wedbush cut their price target on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Royal Bank of Canada decreased their price target on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a research note on Monday, March 3rd. The Goldman Sachs Group decreased their target price on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised their target price on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $45.53.

Apellis Pharmaceuticals Stock Up 1.2 %

Shares of APLS stock opened at $24.66 on Monday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The company’s fifty day moving average price is $28.33 and its 200-day moving average price is $30.50. Apellis Pharmaceuticals, Inc. has a one year low of $23.77 and a one year high of $59.91. The company has a market capitalization of $3.10 billion, a price-to-earnings ratio of -12.15 and a beta of 0.92.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. The business had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue was up 45.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.73) earnings per share. Sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity

In other news, insider Caroline Baumal sold 2,816 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the transaction, the insider now owns 55,560 shares in the company, valued at approximately $1,878,483.60. This trade represents a 4.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Cedric Francois sold 6,247 shares of the firm’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $179,288.90. Following the transaction, the chief executive officer now owns 307,415 shares in the company, valued at approximately $8,822,810.50. This represents a 1.99 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 65,934 shares of company stock worth $1,950,261. Company insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).